<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01704001</url>
  </required_header>
  <id_info>
    <org_study_id>ART-123 IV-2</org_study_id>
    <nct_id>NCT01704001</nct_id>
  </id_info>
  <brief_title>Clinical Pharmacokinetics Study of ART-123 in Disseminated Intravascular Coagulation (DIC) Subjects With Renal Impairment</brief_title>
  <official_title>A Post-Marketing Clinical Pharmacokinetics Study of ART-123 in DIC Subjects With Renal Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asahi Kasei Pharma Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asahi Kasei Pharma Corporation</source>
  <brief_summary>
    <textblock>
      To investigate the impact of impaired renal function on the pharmacokinetics of ART-123 in
      patients with Disseminated Intravascular Coagulation.

      To investigate the safety of ART-123 in patients with Disseminated Intravascular Coagulation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite of Pharmacokinetics</measure>
    <time_frame>pre-dose, 0,2,4,8,24 hours post-dose</time_frame>
    <description>Cmax, Area Under Curve, T1/2,CLtot,CLR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence rate of hemorrhage related adverse events</measure>
    <time_frame>from the start of infusion to 8days after the cessation of infusion</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Disseminated Intravascular Coagulation</condition>
  <arm_group>
    <arm_group_label>Renal impairment grade 0</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Renal impairment grade 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Renal impairment grade 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Renal impairment grade 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ART-123</intervention_name>
    <description>380 U/kg/day or 130 U/kg/day(Subjects with severe renal impairment) for 6 days</description>
    <arm_group_label>Renal impairment grade 0</arm_group_label>
    <arm_group_label>Renal impairment grade 1</arm_group_label>
    <arm_group_label>Renal impairment grade 2</arm_group_label>
    <arm_group_label>Renal impairment grade 3</arm_group_label>
    <other_name>Recomodulinâ„¢</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Japanese Association for Acute Medicine-defined DIC criteria score &gt;= 4

          -  Written informed consent from patient or guardian

        Exclusion Criteria:

          -  Patients showing intracranial, pulmonary, gastrointestinal hemorrhage

          -  Patients with a history of cerebrovascular disorders within the past 52 week

          -  Patients with a history of hypersensitivity to the ingredients of ART-123 preparations

          -  Pregnant women, nursing mothers or possibly pregnant women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Oita</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 1, 2012</study_first_submitted>
  <study_first_submitted_qc>October 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 11, 2012</study_first_posted>
  <last_update_submitted>February 13, 2017</last_update_submitted>
  <last_update_submitted_qc>February 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ART-123</keyword>
  <keyword>Disseminated Intravascular Coagulation</keyword>
  <keyword>Pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Disseminated Intravascular Coagulation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

